 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
2001Abraham CR. Reactive astrocytes and a1-antichymotrypsin in Alzheimer’s disease. Neurobiology of Aging 2001; 22:931-936. [PDF] Demissie S, Green RC, Mucci L, Tziavas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K, Smith T, Sharrow N, Lautenschlager N, Friedland R, Cupples LA, Farrer LA. Reliability of information collected by proxy in family studies of Alzheimer’s disease. Neuroepidemiology 2001; 20:105-111. [PubMed] Farrer LA. Intercontinental epidemiology of Alzheimer disease: a global approach to bad gene hunting. JAMA 2001; 285:796-798. [PDF] Harper DG, Stopa EG, McKee AC, Satlin A, Harlan PC, Goldstein R, Volicer L. Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch Gen Psychiatry 2001; 58:353-360. [PDF] Shcherbatykh TV, Kir’yanov SA, Korovaitseva GI, Selezneva ND, Voskresenskaya NI, Golimbet VE, Farrer L, Gavrilova SI, Rogaev EI. The angiotensin-converting enzyme gene as a possible risk or protective factor in Alzheimer’s disease. Neuroscience and Behavioral Physiology 2001; 31:179-181. [PubMed] Volicer L. Management of severe Alzheimer’s disease and end-of-life issues. Clinics in Geriatric Medicine 2001; 17:377-391. [PubMed] Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. Sundowning and circadian rhythms in Alzheimer’s disease. American Journal of Psychiatry 2001; 158:704-711. [PDF] |
|
 |
 |
 |
 |
 |
|